AL amyloidosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:85443OMIM:254500E85.4E85.9
Who is this for?
Show terms as
1FDA treatments59Active trials70Specialists8Treatment centers5Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

AL Amyloidosis is treated with 1 medication in our database, including Vyndaqel, Vyndamax. Medications are manufactured by Pfizer. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for AL Amyloidosis treatment below.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal pulmonary interstitial morphologyHP:0006530Hepatic amyloidosisHP:0012280AlbuminuriaHP:0012592Decreased QRS voltageHP:0025077Periorbital purpuraHP:0025552Elevated circulating NT-proBNP concentrationHP:0031185Monoclonal light chain cardiac amyloidosisHP:0031326Renal interstitial amyloid depositsHP:0032613Erectile dysfunctionHP:0100639
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
May 2026Evaluation of Skin Tests in Biotherapy Allergies

University Hospital, Angers — NA

TrialNOT YET RECRUITING
Mar 2026A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

GlaxoSmithKline — PHASE2

TrialNOT YET RECRUITING
Feb 2026A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Kedrion S.p.A. — PHASE3

TrialRECRUITING
Jan 2026A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Sinocelltech Ltd. — PHASE3

TrialRECRUITING
Jan 2026Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Peking University People's Hospital — PHASE2

TrialNOT YET RECRUITING
Dec 2025Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. — PHASE1, PHASE2

TrialRECRUITING
Nov 2025One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS

Fondazione IRCCS Policlinico San Matteo di Pavia

TrialRECRUITING
Nov 2025Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment

Fondazione IRCCS Policlinico San Matteo di Pavia

TrialRECRUITING
Nov 2025Teclistamab-Daratumumab in AL Amyloidosis

Suzanne Lentzsch, MD — PHASE2

TrialRECRUITING
Oct 2025Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Gracell Biotechnologies (Shanghai) Co., Ltd. — PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Vyndaqel, Vyndamax

· Pfizer

* Patient Copay Amount: As little as $0 per month * Maximum Annual Benefit Limit: $10,000-$60,000 per calendar year * Core Eligibility Restrictions: Patients must have commercial insurance and be resi

Clinical Trials

20 recruitingView all trials with filters →
Phase 36 trials
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Phase 3
Actively Recruiting
PI: Mirella Calcinai, MD (Medical Director, Clinical Development) · Sites: Phoenix, Arizona; Rochester, Minnesota +1 more · Age: 1870 yrs
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Phase 3
Active Prior treatment eligible
PI: Scott Swenson, MD (Alexion, AstraZeneca Rare Disease) · Sites: Duarte, California; Palo Alto, California +18 more · Age: 1899 yrs
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
Phase 3
Actively Recruiting
· Sites: Beijing, Beijing Municipality · Age: 1899 yrs
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Phase 3
Actively Recruiting
PI: Patrick A Hagen (SWOG Cancer Research Network) · Sites: Derby, Connecticut; Guilford, Connecticut +33 more · Age: 1899 yrs
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Phase 3
Actively Recruiting
PI: Andrew Stephens, MD, PhD (Life Molecular Imaging) · Sites: Kansas City, Kansas; Philadelphia, Pennsylvania +12 more · Age: 1899 yrs
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Phase 3
Active Prior treatment eligible
PI: Scott Swenson, MD (Alexion, AstraZeneca Rare Disease) · Sites: Scottsdale, Arizona; Duarte, California +18 more · Age: 1899 yrs
Phase 21 trial
Teclistamab-Daratumumab in AL Amyloidosis
Phase 2
Actively Recruiting
PI: Suzanne Lentzsch, MD, PhD (Columbia University) · Sites: New York, New York · Age: 18100 yrs
Other13 trials
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Actively Recruiting
· Sites: Bari; Catania +2 more · Age: 1899 yrs
Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Actively Recruiting
· Sites: Pavia, PV · Age: 1899 yrs
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
Enrolling by Invitation
PI: Zhihong Liu, MD (Nanjing University School of Medicine) · Sites: Nanjing, Jiangsu · Age: 1875 yrs
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Actively Recruiting
PI: Don Benson, MD (Ohio State University) · Sites: Columbus, Ohio · Age: 1899 yrs
Registry for Adults With Plasma Cell Disorders (PCD's)
Actively Recruiting
PI: Sascha Tuchman, MD (UNC Lineberger Comprehensive Cancer Center) · Sites: Chapel Hill, North Carolina · Age: 1899 yrs
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Actively Recruiting
· Sites: Birmingham, Alabama; Los Angeles, California +11 more · Age: 4099 yrs
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Actively Recruiting
· Sites: Pavia · Age: 1899 yrs
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Actively Recruiting
· Sites: Beijing
A Registry of AL Amyloidosis (ReAL)
Actively Recruiting
· Sites: Pavia · Age: 1899 yrs
The Norwegian Immunotherapy in Multiple Myeloma Study
Actively Recruiting
· Sites: Arendal; Ålesund +21 more · Age: 1899 yrs
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
Actively Recruiting
· Sites: Heidelberg; Pavia +4 more · Age: 1899 yrs
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
Actively Recruiting
· Sites: Hefei, Anhui; Tianjin, Tianjin Municipality · Age: 1899 yrs
BE.Amycon Biobank & Data Registry UZ Leuven
Actively Recruiting
PI: Michel Delforge (UZ Leuven Gasthuisberg) · Sites: Leuven; Leuven · Age: 1899 yrs

Specialists

Showing 25 of 70View all specialists →
WM
wei dong, MD,PHD
Beijing, Beijing Municipality
Specialist

Rare Disease Specialist

MB
Mario Boccadoro
Specialist
2 AL amyloidosis publications
FK
Farhan Khalid
LONG BRANCH, NJ
Specialist
1 AL amyloidosis publication
AW
Ashutosh D Wechalekar
Specialist
5 AL amyloidosis publications
MZ
Maroun Bou Zerdan
Specialist
1 AL amyloidosis publication
RC
Raymond L Comenzo
BOSTON, MA
Specialist
2 AL amyloidosis publications
VS
Vaishali Sanchorawala
BOSTON, MA
Specialist
4 AL amyloidosis publications
SR
Shahzad Raza
KANSAS CITY, MO
Specialist
2 AL amyloidosis publications
EM
Eli Muchtar
ROCHESTER, MN
Specialist
2 AL amyloidosis publications
YB
Youssef Bouferraa
CLEVELAND, OH
Specialist
1 AL amyloidosis publication
SA
Sabine Allam
Specialist
1 AL amyloidosis publication
FA
Faiz Anwer
TUCSON, AZ
Specialist
2 AL amyloidosis publications
LN
Lewis Nasr
HOUSTON, TX
Specialist
1 AL amyloidosis publication
AD
Angela Dispenzieri
ROCHESTER, MN
Specialist
2 AL amyloidosis publications
SM
Scott Swenson, MD
Duarte, California
Specialist

Rare Disease Specialist

CC
Chakra P Chaulagain
WESTON, FL
Specialist
2 AL amyloidosis publications
HM
Heather Landau, MD
NEW YORK, NY
Specialist
PI on 4 active trials
RM
Raymond Comenzo, MD
BOSTON, MA
Specialist
PI on 4 active trials
JL
Jin Lu
Specialist
PI on 4 active trials
VM
Vaishali Sanchorawala, MD
BOSTON, MA
Specialist
PI on 11 active trials
AM
Angela Dispenzieri, M.D.
ROCHESTER, MN
Specialist
PI on 5 active trials
SM
Shaji K. Kumar, MD
ROCHESTER, MN
Specialist
PI on 5 active trials
AP
Alex A. Adjei, MD, PhD
ROCHESTER, MN
Specialist
PI on 3 active trials

Treatment Centers

8 centers
⚗️ Trial Site

Research Site

📍 Los Angeles, California

👤 AstraZeneca Clinical Study Information Center

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

Travel Grants

5 grants

PAN Foundation Amyloidosis copay grant

PAN Foundation

Applicants must be receiving treatment for amyloidosis in the U.S. and have government-insured health coverage for their medication. Eligible patients must also have a household income at or below 500% of the Federal Poverty Level.

Apply ↗Up to $6,800

The Assistance Fund (TAF) Amyloidosis Financial Assistance Program

The Assistance Fund provides financial assistance to patients and families facing high out-of-pocket medical costs for copayments, coinsurance, and deductibles. Eligibility is generally based on having a diagnosis for a covered disease and demonstrating financial need for health-related expenses.

Apply ↗

WAINUA Way Patient Support Program

Apply ↗

Amyloidosis Foundation Patient Assistance Resources

Amyloidosis Foundation

Apply ↗

WAINUA Savings Program

Apply ↗

Community

Open AL amyloidosisForum →

No community posts yet. Be the first to share your experience with AL amyloidosis.

Start the conversation →

Latest news about AL amyloidosis

Disease timeline:

New recruiting trial: A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: Registry for Adults With Plasma Cell Disorders (PCD's)

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: Teclistamab-Daratumumab in AL Amyloidosis

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: Molecular Imaging of Primary Amyloid Cardiomyopathy

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

A new clinical trial is recruiting patients for AL amyloidosis

New recruiting trial: Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

A new clinical trial is recruiting patients for AL amyloidosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about AL amyloidosis

What is AL amyloidosis?

AL Amyloidosis is treated with 1 medication in our database, including Vyndaqel, Vyndamax. Medications are manufactured by Pfizer. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for AL Amyloidosis treatment below.

How is AL amyloidosis inherited?

AL amyloidosis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does AL amyloidosis typically begin?

Typical onset of AL amyloidosis is adult. Age of onset can vary across affected individuals.

Are there clinical trials for AL amyloidosis?

Yes — 20 recruiting clinical trials are currently listed for AL amyloidosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat AL amyloidosis?

25 specialists and care centers treating AL amyloidosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for AL amyloidosis?

1 FDA-approved treatment are currently tracked on UniteRare for AL amyloidosis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.